









市場行情
/
股票
/
nasdaq-auph
/

Aurinia Pharmaceuticals Inc

AUPH

15.150USD

-0.180-1.17%

收盤 01/09, 16:00（美東）報價延遲15分鐘

2.00B總市值

26.33本益比TTM



Aurinia Pharmaceuticals Inc

15.150

-0.180-1.17%

概覽公司財務分析

概覽

公司

財務

分析

關於 Aurinia Pharmaceuticals Inc 公司

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is also developing aritinercept (AUR200), a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. It sells LUPKYNIS to specialty pharmacies and a specialty distributor in the United States and sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. (Otsuka), for the European and Japanese market. The Company sells encapsulated voclosporin to its collaboration partner, Otsuka, which Otsuka then sells to customers in its territories.

Aurinia Pharmaceuticals Inc簡介



公司代碼AUPH

公司名稱Aurinia Pharmaceuticals Inc

上市日期Jul 16, 2001

CEOGreenleaf (Peter S)

員工數量130

證券類型Ordinary Share

年結日Jul 16

公司地址#140, 14315 - 118 Avenue

城市EDMONTON

上市交易所NASDAQ OMX - NASDAQ BASIC

國家Canada

郵編T5L 4S6

電話12507442487

網址https://www.auriniapharma.com

公司代碼AUPH

上市日期Jul 16, 2001

CEOGreenleaf (Peter S)

Aurinia Pharmaceuticals Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Peter S. Greenleaf

President, Chief Executive Officer, Director

720.08K

+52215.00%

Mr. Stephen P. Robertson

Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary

184.38K

+8173.00%

Ms. Jill Diane Leversage

Independent Director

12.92K

-2825.00%

Dr. Greg Keenan

Chief Medical Officer

10.51K

-142976.00%

Dr. David R.W Jayne, M.D.

Independent Director

Mr. Matthew (Max) Donley

Chief Operating Officer

Mr. Joseph Miller

Chief Financial Officer

Dr. Karen Lesley Smith, M.D., Ph.D.

Independent Director

Mr. Jeffrey A. Bailey

Independent Director

Mr. Kevin Tang

Independent Chairman of the Board

名稱

名稱/職務

職務

持股

持股變動

Mr. Peter S. Greenleaf

President, Chief Executive Officer, Director

720.08K

+52215.00%

Mr. Stephen P. Robertson

Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary

184.38K

+8173.00%

Ms. Jill Diane Leversage

Independent Director

12.92K

-2825.00%

Dr. Greg Keenan

Chief Medical Officer

10.51K

-142976.00%

Dr. David R.W Jayne, M.D.

Independent Director

Mr. Matthew (Max) Donley

Chief Operating Officer

收入明細

單位: USD更新時間: 1月6日週二

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

由於公司未披露，未能獲取相關數據

地區USD

名稱

營收

佔比

210.09M

89.35%

Japan

25.04M

10.65%

Other

0.00

0.00%

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 1月7日週三

持股股東

股東類型

持股股東

佔比

Tang Capital Management, LLC

8.59%

ILJIN SNT Co., Ltd.

4.96%

BlackRock Institutional Trust Company, N.A.

4.72%

New Enterprise Associates (NEA)

3.01%

Arrowstreet Capital, Limited Partnership

2.56%

其他

76.16%

持股股東

佔比

Tang Capital Management, LLC

8.59%

ILJIN SNT Co., Ltd.

4.96%

BlackRock Institutional Trust Company, N.A.

4.72%

New Enterprise Associates (NEA)

3.01%

Arrowstreet Capital, Limited Partnership

2.56%

其他

76.16%

股東類型

持股股東

佔比

Investment Advisor/Hedge Fund

15.27%

Hedge Fund

15.04%

Investment Advisor

12.88%

Corporation

4.96%

Research Firm

3.21%

Venture Capital

3.03%

Individual Investor

2.48%

Pension Fund

0.78%

Bank and Trust

0.31%

其他

42.05%

機構持股



更新時間: 12月8日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

445

66.60M

50.51%

+1.59M

2025Q3

456

66.87M

50.55%

+7.38M

2025Q2

441

59.25M

53.54%

-3.86M

2025Q1

434

64.06M

48.83%

-3.20M

2024Q4

431

60.29M

49.51%

-113.45K

2024Q3

429

60.37M

47.88%

+2.19M

2024Q2

432

58.67M

47.42%

+718.51K

2024Q1

426

57.94M

45.47%

-7.82M

2023Q4

439

56.12M

43.33%

+3.78M

2023Q3

448

52.25M

45.32%

-2.45M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Tang Capital Management, LLC

11.33M

8.59%

+1.30M

+12.96%

Sep 30, 2025

ILJIN SNT Co., Ltd.

6.54M

4.96%

-984.75K

-13.10%

Aug 12, 2025

BlackRock Institutional Trust Company, N.A.

6.22M

4.72%

-241.10K

-3.73%

Sep 30, 2025

New Enterprise Associates (NEA)

3.97M

3.01%

Sep 30, 2025

Arrowstreet Capital, Limited Partnership

3.37M

2.56%

+2.30M

+213.54%

Sep 30, 2025

State Street Investment Management (US)

2.69M

2.04%

-101.33K

-3.63%

Sep 30, 2025

Two Sigma Investments, LP

1.83M

1.39%

+1.48M

+417.21%

Sep 30, 2025

The Vanguard Group, Inc.

1.53M

1.16%

-163.37K

-9.65%

Sep 30, 2025

Geode Capital Management, L.L.C.

1.49M

1.13%

-91.36K

-5.79%

Sep 30, 2025

Marshall Wace LLP

1.48M

1.12%

+1.38M

+1272.51%

Sep 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

Virtus LifeSci Biotech Products ETF

2.56%

Janus Henderson Small Cap Growth Alpha ETF

2.33%

Janus Henderson Small/Mid Cap Growth Alpha ETF

1.09%

ALPS Medical Breakthroughs ETF

0.7%

ProShares Ultra Nasdaq Biotechnology

0.26%

JPMorgan Diversified Return U.S. Small Cap Equity ETF

0.26%

SPDR S&P International Small Cap ETF

0.2%

Vanguard US Multifactor ETF

0.18%

Invesco Nasdaq Biotechnology ETF

0.17%

Avantis US Small Cap Equity ETF

0.16%

Virtus LifeSci Biotech Products ETF

佔比2.56%

Janus Henderson Small Cap Growth Alpha ETF

佔比2.33%

Janus Henderson Small/Mid Cap Growth Alpha ETF

佔比1.09%

ALPS Medical Breakthroughs ETF

佔比0.7%

ProShares Ultra Nasdaq Biotechnology

佔比0.26%

JPMorgan Diversified Return U.S. Small Cap Equity ETF

佔比0.26%

SPDR S&P International Small Cap ETF

佔比0.2%

Vanguard US Multifactor ETF

佔比0.18%

Invesco Nasdaq Biotechnology ETF

佔比0.17%

Avantis US Small Cap Equity ETF

佔比0.16%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Aurinia Pharmaceuticals Inc的前五大股東是誰？



Aurinia Pharmaceuticals Inc的前五大股東如下：
Tang Capital Management, LLC
持有股份：11.33M
佔總股份比例：8.59%。
ILJIN SNT Co., Ltd.
持有股份：6.54M
佔總股份比例：4.96%。
BlackRock Institutional Trust Company, N.A.
持有股份：6.22M
佔總股份比例：4.72%。
New Enterprise Associates (NEA)
持有股份：3.97M
佔總股份比例：3.01%。
Arrowstreet Capital, Limited Partnership
持有股份：3.37M
佔總股份比例：2.56%。